高悪性度神経膠腫 - 市場考察、疫学、市場予測（2034年）

主なハイライト

• 2023年、高悪性度神経膠腫の総市場規模は主要7市場で最大8億3,000万米ドルとなりました。
• 米国のFDAに提出されたがん治療用新薬治験申請のうち、成功するのはわずか5%であり、脳腫瘍の成功率は過去20年間で1%に近いです。
• 現在、米国では毎年最大2万5,000件の悪性脳腫瘍が新たに診断されていると推定されています。その約80％が神経膠腫です。毎年診断される膠芽腫の総数は約1万3,000件です。
• 退形成性星細胞腫と膠芽腫は年齢とともに罹患率が増加し、75～84歳でピークに達します。
• 膠芽腫パイプラインの一部として、ファーストラインとセカンドラインの膠芽腫に対する数多くのがんワクチンが開発段階にあります。樹状細胞がんワクチンでまだ成功を収めていないNorthwest Therapeuticsなど、多くの企業が膠芽腫で成功を収めようと何十年も試みています。
• 2024年5月、Imvaxは、新たに膠芽腫と診断された患者を対象としたIGV-001の無作為化多施設二重盲検プラセボ対照フェーズIIb臨床試験の登録完了を発表しました。
• CNS Pharmaceuticalsは、極めて重要な可能性を持つGBM試験において、ベルビシンのフェーズII試験の登録が完了し、2025年前半にトップラインデータが予測されると発表しました。

高悪性度神経膠腫市場の見通し

膠芽腫の治療にもっともよく使用される化学療法薬はTEMODAR/TEMODALです。これはアルキル化剤として知られる薬剤のクラスに属し、がん細胞の成長を遅らせたり止めたりすることで効果を発揮します。免疫療法は治療の新たな機会を提供します。免疫療法は、体の免疫系を活性化させて腫瘍と闘い、腫瘍の増殖を止めることを目的とした、新しい有望で刺激的な治療法です。免疫療法あるいは"ワクチン"療法は、個々の腫瘍に対して免疫応答を誘導することを含みます。現在、H3K27M変異に対する治療法の開発が進んでいるのはChimerixだけです。開発の初期段階にあるその他の主要企業には、Rigel Pharmaceuticals、Aminex Therapeutics、Bexion Pharmaceuticals、OX2 Therapeutics、Neonc Technologiesなどがあります。GBMの新興市場には、VBL Therapeuticsによる萌芽的な遺伝子治療があり、DCVax-L、SurVaxMなどのワクチン/免疫療法候補がそれに続いていることは興味深いです。がん新薬はコストが高く、開発期間が長く、承認率が低いため、承認済みの薬剤を潜在的ながん治療に再利用することへの関心が高まっています。投与スケジュールや毒性プロファイルが確立されたこれらの薬剤を利用することで、治療薬として導入するために必要な時間と費用を大幅に削減することができます。

• 高悪性度神経膠腫の市場規模は、主要7市場において米国がもっとも大きく、2023年に約5億8,000万米ドルに達しました。
• 欧州4ヶ国・英国の中では、ドイツが2023年に最大の市場規模を占め、スペインは最下位でした。
• すべての治療法の中で、2034年までに主要7市場でDCVax-Lがもっとも高い収益を上げ、ONC-201がそれに続くと予測されます。

当レポートでは、高悪性度神経膠腫の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 高悪性度神経膠腫のエグゼクティブサマリー

第4章 主な出来事

第5章 疫学と市場予測の調査手法

第6章 高悪性度神経膠腫市場の概要

• 高悪性度神経膠腫の市場シェアの分布：治療法別（2023年）
• 高悪性度神経膠腫の市場シェアの分布：治療法別（2034年）

第7章 疾患の背景と概要

• イントロダクション
• 神経膠腫の分類
• 分子分析
• 兆候と症状
• 原因
• 診断
• 治療と管理
• ガイドライン

第8章 疫学と患者人口

• 主な調査結果
• 主要7市場の神経膠腫の総発症数
• 主要7市場の高悪性度神経膠腫の総発症数
• 米国
• 欧州4ヶ国・英国
• 日本

第9章 ペイシェントジャーニー

第10章 高悪性度神経膠腫における主な評価項目

第11章 上市済み薬品

• 主な競合
• AVASTIN (BEVACIZUMAB): ROCHE (GENENTECH)
• TEMODAR/TEMODAL (TEMOZOLOMIDE): MERCK
• DELYTACT (TESERPATUREV/G47): DAIICHI SANKYO
• TAFINLAR (DABRAFENIB) + MEKINIST (TRAMETINIB): NOVARTIS
• OPTUNE GIO: NOVOCURE

第12章 新薬

• 主な競合
• ONC201: CHIMERIX
• AV-GBM-1: AIVITA BIOMEDICAL
• ENZASTAURIN (DB-102): DENOVO BIOPHARMA
• DCVAX-L: NORTHWEST THERAPEUTICS
• EFLORNITHINE: ORBUS THERAPEUTICS
• TVI-BRAIN-1: TVAX BIOMEDICAL
• LAM561 (2-OHOA): LAMINAR PHARMACEUTICALS
• REC-2282: RECURSION PHARMACEUTICALS
• VT1021: VIGEO THERAPEUTICS
• VERZENIO (ABEMACICLIB): ELI LILLY
• PEMAZYRE (PEMIGATINIB): INCYTE CORPORATION
• PAXALISIB (GDC-0084): KAZIA THERAPEUTICS
• BMX-001: BIOMIMETIX
• BIZAXOFUSP (MDNA55): MEDICENNA THERAPEUTICS
• ITI-1000 (PP65 DC VACCINE): IMMUNOMIC THERAPEUTICS
• SURVAXM: MIMIVAX
• OKN-007: OBLATO
• BERUBICIN: CNS PHARMACEUTICALS
• GLIOVAC/SITOIGANAP: EPITOPOIETIC RESEARCH CORPORATION (ERC)
• IGV-001: IMVAX
• BGB-290: BEIGENE
• EO2401: ENTEROME
• VBI-1901: VBI VACCINES
• TEMFERON: GENENTA SCIENCE
• NOX-A12 (OLAPTESED PEGOL): TME PHARMA
• INO-5401+ INO-9012+ LIBTAYO (CEMIPLIMAB): INOVIO PHARMACEUTICALS
• LERAPOLTUREV: ISTARI ONCOLOGY
• RHENIUM (186RE) OBISBEMEDA: PLUS THERAPEUTICS

第13章 神経膠腫：主要7市場の分析

• 主な調査結果
• 市場見通し
• 主な市場予測の前提条件
• コンジョイント分析
• 主要7市場のHGGの総市場規模
• 米国の市場規模
  • 米国のHGGの総市場規模
  • 米国のHGGの市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のHGGの総市場規模
  • ドイツのHGGの市場規模：治療法別
  • 英国のHGGの市場規模：治療法別
• 日本の市場規模
  • 日本のHGGの総市場規模

第14章 アンメットニーズ

第15章 SWOT

第16章 KOLの見解

第17章 市場参入と償還

• 米国
• 欧州
• 日本

第18章 付録

第19章 DelveInsightの機能

第20章 免責事項

第21章 DelveInsightについて

List of Tables

• Table 1: Summary of High-grade Glioma Market and Epidemiology (2020-2034)
• Table 2: Grading Within Types
• Table 3: Key Treatment Recommendations for Adult Patients with Common Diffuse Gliomas by EANO
• Table 4: Total Incident Cases of Glioma in the 7MM (2020-2034)
• Table 5: Total Incident Cases of High-grade Glioma in the 7MM (2020-2034)
• Table 6: Total Incident Cases of Glioma in the US (2020-2034)
• Table 7: Total Incident Cases of High-grade Glioma in the US (2020-2034)
• Table 8: Total Incident Cases of DIPG/DMG in the US (2020-2034)
• Table 9: Total Incident Cases of H3 K27M Mutant Glioma in the US (2020-2034)
• Table 10: Incident Cases of High-grade Glioma by Major Histological Type in the US (2020-2034)
• Table 11: Age-specific Cases of High-grade Glioma in the US (2020-2034)
• Table 12: Total Incident Cases of Glioma in EU4 and the UK (2020-2034)
• Table 13: Total Incident Cases of High-grade Glioma in EU4 and the UK (2020-2034)
• Table 14: Total Incident Cases of DIPG/DMG in EU4 and the UK (2020-2034)
• Table 15: Total Incident Cases of H3 K27M Mutant Glioma EU4 and the UK (2020-2034)
• Table 16: Incident High-grade Glioma by Major Histological Type in EU4 and the UK (2020-2034)
• Table 17: Age-specific Cases of Glioblastoma in EU4 and the UK (2020-2034)
• Table 18: Age-specific Cases of Anaplastic Astrocytoma in EU4 and the UK (2020-2034)
• Table 19: Total Incident Cases of Glioma in Japan (2020-2034)
• Table 20: Total Incident Cases of High-grade Glioma in Japan (2020-2034)
• Table 21: Total Incident Cases of DIPG/DMG in Japan (2020-2034)
• Table 22: Total Incident Cases of H3 K27M Mutant Glioma in Japan (2020-2034)
• Table 23: Incident High-grade Glioma by Major Histological Type in Japan (2020-2034)
• Table 24: Age-specific Cases of High-grade Glioma in Japan (2020-2034)
• Table 25: Comparison of Marketed Drugs
• Table 26: TEMODAR, Clinical Trial Description, 2024
• Table 27: OPTUNE GIO, Clinical Trial Description, 2024
• Table 28: Comparison of Emerging Drugs
• Table 29: ONC201, Clinical Trial Description, 2024
• Table 30: AV-GBM-1, Clinical Trial Description, 2024
• Table 31: Enzastaurin, Clinical Trial Description, 2024
• Table 32: DCVAX-L, Clinical Trial Description, 2024
• Table 33: Eflornithine, Clinical Trial Description, 2024
• Table 34: TVI-Brain-1, Clinical Trial Description, 2024
• Table 35: LAM561, Clinical Trial Description, 2024
• Table 36: REC-2282, Clinical Trial Description, 2024
• Table 37: VT1021, Clinical Trial Description, 2024
• Table 38: VERZENIO, Clinical Trial Description, 2024
• Table 39: Pemigatinib, Clinical Trial Description, 2024
• Table 40: Paxalisib (GDC-0084), Clinical Trial Description, 2024
• Table 41: BMX-001, Clinical Trial Description, 2024
• Table 42: MDNA55, Clinical Trial Description, 2024
• Table 43: ITI-1000, Clinical Trial Description, 2024
• Table 44: SurVaxM, Clinical Trial Description, 2024
• Table 45: OKN-007, Clinical Trial Description, 2024
• Table 46: Berubicin, Clinical Trial Description, 2024
• Table 47: GLIOVAC/SITOIGANAP, Clinical Trial Description, 2024
• Table 48: Igv-001, Clinical Trial Description, 2024
• Table 49: BGB-290, Clinical Trial Description, 2024
• Table 50: EO2401, Clinical Trial Description, 2024
• Table 51: VBI-1901, Clinical Trial Description, 2024
• Table 52: Temferon, Clinical Trial Description, 2024
• Table 53: NOX-A12, Clinical Trial Description, 2024
• Table 54: INO-5401+ INO-9012+ LIBTAYO, Clinical Trial Description, 2024
• Table 55: Lerapolturev, Clinical Trial Description, 2024
• Table 56: Rhenium (186Re) Obisbemeda, Clinical Trial Description, 2024
• Table 57: Limitations of Current Treatments in Glioblastoma
• Table 58: Total Market Size of HGG in the 7MM, USD million (2020-2034)
• Table 59: Total Market Size of HGG in the United States, USD million (2020-2034)
• Table 60: Market Size of HGG by Therapies in the United States, USD million (2020-2034)
• Table 61: Total Market Size of HGG in EU4 and the UK, USD million (2020-2034)
• Table 62: Market Size of HGG by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 63: Total Market Size of HGG in Japan, USD million (2020-2034)
• Table 64: Market Size of HGG by Therapies in Japan, USD million (2020-2034)
• Table 65: TEMODAL Reimbursement in France
• Table 66: NICE Assessment for TEMODAL
• Table 67: NICE Assessment for TAFINLAR + MEKINIST

List of Figures

• Figure 1: Changes From WHO 2016 to 2021 Classification
• Figure 2: Diagnostic Flowchart of Diffuse Gliomas in Adults and Pediatrics
• Figure 3: Total Incident Cases of Glioma in the 7MM (2020-2034)
• Figure 4: Total Incident Cases of High-grade Glioma in the 7MM (2020-2034)
• Figure 5: Total Incident Cases of Glioma in the US (2020-2034)
• Figure 6: Total Incident Cases of High-grade Glioma in the US (2020-2034)
• Figure 7: Total Incident Cases of DIPG/DMG in the US (2020-2034)
• Figure 8: Total Incident Cases of H3 K27M Mutant Glioma in the US (2020-2034)
• Figure 9: Incident Cases of High-grade Glioma by Major Histological Type in the US (2020-2034)
• Figure 10: Age-specific Cases of Glioblastoma in the US (2020-2034)
• Figure 11: Age-specific Cases of Anaplastic Astrocytoma in the US (2020-2034)
• Figure 12: Total Incident Cases of Glioma in EU4 and the UK (2020-2034)
• Figure 13: Total Incident Cases of High-grade Glioma in EU4 and the UK (2020-2034)
• Figure 14: Total Incident Cases of DIPG/DMG in EU4 and the UK (2020-2034)
• Figure 15: Total Incident Cases of H3 K27M Mutant Glioma in EU4 and the UK (2020-2034)
• Figure 16: Incident Cases of High-grade Glioma by Major Histological Type in EU4 and the UK (2020-2034)
• Figure 17: Age-specific Cases of Glioblastoma in EU4 and the UK (2020-2034)
• Figure 18: Age-specific Cases of Anaplastic Astrocytoma in EU4 and the UK (2020-2034)
• Figure 19: Total Incident Cases of Glioma in Japan (2020-2034)
• Figure 20: Total Incident Cases of High-grade Glioma in Japan (2020-2034)
• Figure 21: Total Incident Cases of DIPG/DMG in Japan (2020-2034)
• Figure 22: Total Incident Cases of H3 K27M Mutant Glioma in Japan (2020-2034)
• Figure 23: Incident Cases of High-grade Glioma by Major Histological Type in Japan (2020-2034)
• Figure 24: Age-specific Cases of Glioblastoma in Japan (2020-2034)
• Figure 25: Age-specific Cases of Anaplastic Astrocytoma in Japan (2020-2034)
• Figure 26: GBM AGILE two-stage Study Design
• Figure 27: Challenges that hamper GBM vaccine efficacy
• Figure 28: Drug Evaluating on the GBM AGILE Platform
• Figure 29: Key Player Developing Therapies for H3K27 M Mutation
• Figure 30: Total Market Size of HGG in the 7MM (2020-2034)
• Figure 31: Total Market Size of HGG in the United States (2020-2034)
• Figure 32: Market size of HGG by Therapies in the United States (2020-2034)
• Figure 33: Total Market Size of HGG in EU4 and the UK (2020-2034)
• Figure 34: Market size of HGG by Therapies in EU4 and the UK (2020-2034)
• Figure 35: Total Market Size of HGG in Japan (2020-2034)
• Figure 36: Market size of HGG by Therapies in Japan (2020-2034)

Key Highlights:

• In 2023, the total market size of high-grade glioma accounted for ~USD 830 million in the 7MM.
• Only 5% of new investigational drug applications submitted to the US FDA for cancer therapies are successful, and for brain cancer, the rate of success has been closer to 1% over the past two decades.
• Currently, there is an estimation of ~25,000 newly diagnosed cases of malignant brain tumors each year in the US. Around 80% of which are gliomas. The total number of glioblastomas diagnosed each year is around 13,000 cases.
• Anaplastic astrocytoma and glioblastoma increase in incidence with age, peaking in the 75-84 age group.
• Numerous cancer vaccines for first-line and second-line glioblastoma are in the development phases as part of the glioblastoma pipeline. Many companies have been attempting for decades to achieve success in glioblastoma, such as Northwest Therapeutics, which has yet to achieve success with its dendritic cell cancer vaccine.
• In May 2024, Imvax announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase IIb clinical trial of IGV-001 in patients with newly diagnosed glioblastoma.
• CNS Pharmaceuticals announced that the enrollment of the Phase II trial of berubicin was completed in a potentially pivotal GBM study, and the topline data is expected in the first half of 2025.

DelveInsight's "High-grade Glioma (HGG) - Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of high-grade glioma, historical and forecasted epidemiology as well as the high-grade glioma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The high-grade glioma market report provides current treatment practices, emerging drugs, high-grade glioma market share of individual therapies, and current and forecasted high-grade glioma market size from 2020 to 2034, segmented by seven major markets. The report also covers current high-grade glioma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

High-grade Glioma (HGG) Disease Understanding and Treatment Algorithm

High-grade Glioma Overview

Highly malignant or high-grade gliomas are tumors of the central nervous system (CNS), wherein high-grade means glioma is proliferating. They are solid tumors arising from transformed brain and/or spinal cord cells. Since they directly originate from the CNS, they are also called primary CNS tumors, differentiating them from malignant tumors of other organs that have spread (metastasized) to the CNS. High-grade gliomas can occur in different parts of the central nervous system and can affect children of any age. The tumors most often originate in the supratentorial region of the brain and the brain stem; high-grade gliomas originating from the supratentorial region are often called supratentorial high-grade gliomas. Symptoms primarily result from the pressure the tumor first exerts on the adjacent brain tissue and, later on, in an advanced stage, on the entire brain (or spinal cord). The local swelling (edema) of adjacent normal brain (or spinal cord) tissue caused by the tumor plays a major role during the development of clinical symptoms.

High-grade Glioma Diagnosis

The initial diagnostic procedures for a patient presenting with a suspected CNS tumor at a childhood cancer center include an assessment of the patient's history, a thorough physical/neurological exam, and imaging diagnostic, such as magnetic resonance imaging (MRI). The MRI is needed to determine the tumor's localization, size, and demarcation from the surrounding brain (or spinal cord) tissue.

Further details related to diagnosis will be provided in the report...

High-grade Glioma Treatment

Treatment for high-grade glioma usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since glioblastomas develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient's brain function and sparing healthy tissues. After surgery, residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy.

Further details related to treatment will be provided in the report...

High-grade Glioma (HGG) Epidemiology

The high-grade glioma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incident cases of glioma, total incident cases of high-grade glioma, total incident cases of DIPG/DMG, total incident cases of H3 K27M mutant glioma, incident cases of high-grade glioma by major histological type, and age-specific cases of high-grade glioma in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In the 7MM, the US accounted for the highest number of incident cases of high-grade glioma, with nearly 16,200 in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of cases of high-grade glioma, followed by France, whereas Spain occupied the bottom of the ladder.
• The number of incident cases of glioblastoma is much higher than that of anaplastic astrocytoma. In the US, in 2023, the former accounted for nearly 13,100, while the latter accounted for nearly 1,600.
• Among the age-specific cases, adult patients occupy a much higher number than that of pediatric patients.

High-grade Glioma Drug Chapters

The drug chapter segment of the high-grade glioma report encloses a detailed analysis of the late-stage (Phase III and Phase II/III) and early-stage (Phase I/II) pipeline drugs. The current key players for emerging drugs and their respective drug candidates include Chimerix/Oncoceutics (ONC201), Immunomic Therapeutics (ITI-1000), MimiVax (SurVaxM), Aivita Biomedical (AV-GBM-1), DNAtrix (DNX-2401), and others. The drug chapter also helps understand the high-grade glioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

Marketed Drugs

TEMODAR/TEMODAL (temozolomide): Merck

The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for treating several brain cancer forms, e.g., as a second-line treatment for astrocytoma and a first-line treatment for GBM. The therapeutic benefit of TEMODAR is its ability to alkylate/methylate DNA. TEMODAR is indicated for the treatment of adults with newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment and anaplastic astrocytoma. It was granted the first US FDA approval in 1999 for recurrent anaplastic astrocytoma. In September 2023, the US FDA approved new and updated indications for TEMODAR capsules and injections, including for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma and the treatment of adults with refractory anaplastic astrocytoma.

AVASTIN (bevacizumab): Roche (Genentech)

AVASTIN is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). It binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. AVASTIN is indicated for treating GBM with progressive disease in adult patients following prior therapy. In December 2017, the US FDA granted full approval for AVASTIN for the treatment of adults with glioblastoma that progressed following prior therapy. AVASTIN was previously granted provisional approval in this setting under the FDA's accelerated approval program. Currently, the US FDA has approved five biosimilars of AVASTIN.

Emerging Drugs

ONC201: Chimerix/Oncoceutics

ONC201 is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that can penetrate the blood-brain barrier effectively. ONC201 engages proven anticancer pathways that lead to apoptosis in cancer cells. It is a small molecule originally identified as a TNF-related apoptosis-inducing ligand (TRAIL) - inducing compound. ONC201 is being evaluated in the Phase III ACTION trial for treating patients with diffuse glioma, or diffuse midline glioma (DMG), which harbor an H3 K27M mutation.

The company anticipates the interim overall survival data by 2025 and the final overall survival data by 2026 from the Phase III ACTION study of ONC201.

ITI-1000: Immunomic Therapeutics

Immunomic Therapeutics is developing ITI-1000 (pp65 DC vaccine), which is a cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 as a fusion protein with the short lysosome-associated membrane protein (shLAMP), with potential immunostimulatory and antineoplastic activities. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled Phase II study in patients with newly diagnosed GBM.

SurVaxM: MimiVax

SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95% of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients' immune response to control tumor growth and recurrence. It is delivered through simple subcutaneous injection. The company is currently evaluating it in the Phase II (SURVIVE) clinical trial.

In May 2024, the US FDA granted a supplemental orphan drug designation to the SurVaxM vaccine to include malignant glioma. In October 2023, the US FDA granted Fast Track Designation to the SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma.

Drug Class Insight

Few targeted therapies inhibit specific molecular targets involved in signaling pathways. A few common targets include EGFR (epidermal growth factor receptor), mTOR (mammalian target of rapamycin), PI3K (phosphatidylinositol 3-kinase), and VEGF (vascular endothelial growth factor). AVASTIN belongs to VEGF inhibitors. Numerous clinical trials are testing new therapeutic approaches with tyrosine kinase inhibitors and angiogenesis inhibitors. ONC-201 selectively targets DRD2 and ClpP and has demonstrated remarkable efficacy in patients with gliomas that carry the H3K27M mutation.

High-grade Glioma Market Outlook

The most commonly used chemotherapy drug to treat glioblastoma is TEMODAR/TEMODAL. It belongs to a class of drugs known as alkylating agents that work by slowing or stopping the growth of cancer cells. Immunotherapy provides another opportunity for treatment. It is a new, promising, exciting treatment area designed to trigger the body's immune system to fight and halt tumor growth. Immunotherapy or "vaccine" therapy involves the induction of an immune response against an individual tumor. Currently, Chimerix is the only company in the advanced stages of developing treatments for the H3K27M mutation. Other key players in the early stages of development include Rigel Pharmaceuticals, Aminex Therapeutics, Bexion Pharmaceuticals, OX2 Therapeutics, Neonc Technologies, and others. It is interesting to note that the emerging market of GBM includes budding gene therapy by VBL Therapeutics, followed by a few vaccine/immunotherapy candidates such as DCVax-L, SurVaxM, and others. Due to the high costs, lengthy development period, and low approval rate of new oncology drugs, there is a growing interest in repurposing approved drugs for potential cancer treatments. Utilizing these drugs, with established dosing schedules and toxicity profiles, can significantly cut down on the time and expenses required to introduce them as treatments.

• The US accounted for the largest market size of high-grade glioma in the 7MM, with nearly USD 580 million in 2023.
• Among EU4 and the UK, Germany accounted for the maximum market size in 2023, while Spain occupied the bottom of the ladder.
• Among all the therapies, DCVax-L is expected to generate the highest revenue followed by ONC-201 in the 7MM by 2034.

Further details will be provided in the report....

High-grade Glioma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to be launched in the market during the study period. The analysis covers high-grade glioma market uptake by drugs; patient uptake by therapies; and sales of each drug. As per the analysis, SurVaxM + temozolomide +- sargramostim drug uptake in the US is expected to be medium-fast. Out of all the vaccines in the pipeline, SurVaxM and DCVax-L are top contenders in the first-line setting. DCVax-L is also among the few top contenders in the second-line setting.

High-grade Glioma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for high-grade glioma emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professor and Vice Chair Department of Critical Care Medicine and Director, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or high-grade glioma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Delveinsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Radiation and Oncology Miami Cancer Institute, Johns Hopkins University School of Medicine, University of California, etc., were contacted. Their opinion helps understand and validate high-grade glioma epidemiology and market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as USD USD 0 per treatment for AVASTIN. Co-pay assistance of up to USD 25,000 is provided per calendar year. An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times, and the type or amount of assistance available (if any) can vary by foundation. Independent co-pay assistance foundations have their own eligibility rules. They have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help. They can only refer the patients to a foundation that supports the disease state.

Further detailed analysis will be provided in the report....

Scope of the Report:

• The report covers a descriptive overview of high-grade glioma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into high-grade glioma epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for high-grade glioma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the high-grade glioma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM high-grade glioma market.

High-grade Glioma Report Insights

High-grade Glioma Report Insights

• Patient Population
• Therapeutic Approaches
• High-grade Glioma Pipeline Analysis
• High-grade Glioma Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

High-grade Glioma Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• High-grade Glioma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

High-grade Glioma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the high-grade glioma market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the high-grade glioma total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings about the market across the 7MM and which country will have the largest high-grade glioma market size during the study period (2020-2034)?
• At what CAGR, the high-grade glioma market is expected to grow at the 7MM level during the study period (2020-2034)?
• What would be the high-grade glioma market outlook across the 7MM during the study period (2020-2034)?
• What would be the high-grade glioma market growth till 2034 and what will be the resultant market size in the year 2034?
• What are the disease risks, burdens, and unmet needs of high-grade glioma?
• What is the historical high-grade glioma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), and the UK, and Japan?
• What would be the forecasted patient pool of high-grade glioma at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population of high-grade glioma?
• Out of the above-mentioned countries, which country would have the incident population of high-grade glioma during the study period (2020-2034)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2020-2034)?
• How many companies are developing therapies for the treatment of high-grade glioma?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of high-grade glioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to high-grade glioma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for high-grade glioma and their status?
• What are the key designations that have been granted for the emerging therapies for high-grade glioma?
• What are the 7MM historical and forecasted market of high-grade glioma?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving high-grade glioma.
• To understand the future market competition in the high-grade glioma market and Insightful review of the SWOT analysis of high-grade glioma.
• Organize sales and marketing efforts by identifying the best opportunities for high-grade glioma in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the high-grade glioma market.
• To understand the future market competition in the high-grade glioma market.

Table of Contents

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY OF HIGH-GRADE GLIOMA

4. KEY EVENTS

5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

6. HIGH-GRADE GLIOMA MARKET OVERVIEW AT A GLANCE

• 6.1. MARKET SHARE (%) DISTRIBUTION OF HIGH-GRADE GLIOMA BY THERAPIES IN 2023
• 6.2. MARKET SHARE (%) DISTRIBUTION OF HIGH-GRADE GLIOMA BY THERAPIES IN 2034

7. DISEASE BACKGROUND AND OVERVIEW

• 7.1. INTRODUCTION
• 7.2. CLASSIFICATION OF GLIOMAS
• 7.3. MOLECULAR ANALYSIS
• 7.4. SIGNS AND SYMPTOMS
• 7.5. CAUSES
• 7.6. DIAGNOSIS
• 7.7. TREATMENT AND MANAGEMENT
• 7.8. GUIDELINES
  • 7.8.1. NCCN Guidelines for the Management of Gliomas (2024)
  • 7.8.2. American Society for Clinical Oncology (ASTRO) - Society for Neuro-Oncology (SNO) Guidelines for Therapy of Diffuse Astrocytic and Oligodendroglial Tumors in Adults
  • 7.8.3. The Japan Society for Neuro-Oncology Guidelines for Glioblastoma
  • 7.8.4. Spanish Society of Medical Oncology (SEOM) - Spanish Group of Investigation in Neuro-Oncology (GEINO) Guidelines High-grade Gliomas of Adulthood (2022)
  • 7.8.5. Clinical Recommendation for Glioblastoma (Associazione Italiana di Oncologia Medica [AIOM], 2021)
  • 7.8.6. European Association for Neuro-Oncology (EANO) Guidelines for Diagnosis and Treatment of Diffuse Gliomas of Adulthood

8. EPIDEMIOLOGY AND PATIENT POPULATION

• 8.1. KEY FINDINGS
• 8.2. TOTAL INCIDENT CASES OF GLIOMA IN THE 7MM
• 8.3. TOTAL INCIDENT CASES OF HIGH-GRADE GLIOMA IN THE 7MM
• 8.4. THE UNITED STATES
  • 8.4.1. Total Incident Cases of Glioma in the US
  • 8.4.2. Total Incident Cases of High-grade Glioma in the United States
  • 8.4.3. Total Incident Cases of DIPG/DMG in the United States
  • 8.4.4. Total Incident Cases of H3 K27M Mutant Glioma in the United States
  • 8.4.5. Incident Cases of High-grade Glioma by Major Histological Type in the United States
  • 8.4.6. Age-specific Cases of High-grade Glioma in the United States
• 8.5. EU4 AND THE UK
  • 8.5.1. Total Incident Cases of Glioma in EU4 and the UK
  • 8.5.2. Total Incident Cases of High-grade Glioma in EU4 and the UK
  • 8.5.3. Total Incident Cases of DIPG/DMG in EU4 and the UK
  • 8.5.4. Total Incident Cases of H3 K27M Mutant Glioma in EU4 and the UK
  • 8.5.5. Incident Cases of High-grade Glioma by Major Histological Type in EU4 and the UK
  • 8.5.6. Age-specific Cases of High-grade Glioma in EU4 and the UK
• 8.6. JAPAN
  • 8.6.1. Total Incident Cases of Glioma in Japan
  • 8.6.2. Total Incident Cases of High-grade Glioma in Japan
  • 8.6.3. Total Incident Cases of DIPG/DMG in Japan
  • 8.6.4. Total Incident Cases of H3 K27M Mutant Glioma in Japan
  • 8.6.5. Incident Cases of High-grade Glioma by Major Histological Type in Japan
  • 8.6.6. Age-specific Cases of High-grade Glioma in Japan

9. PATIENT JOURNEY

10. KEY ENDPOINTS IN HIGH-GRADE GLIOMA

11. MARKETED DRUGS

• 11.1. KEY COMPETITORS
• 11.2. AVASTIN (BEVACIZUMAB): ROCHE (GENENTECH)
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Product Profile
• 11.3. TEMODAR/TEMODAL (TEMOZOLOMIDE): MERCK
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Clinical Development
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Product Profile
• 11.4. DELYTACT (TESERPATUREV/G47?): DAIICHI SANKYO
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Safety and Efficacy
  • 11.4.4. Product Profile
• 11.5. TAFINLAR (DABRAFENIB) + MEKINIST (TRAMETINIB): NOVARTIS
  • 11.5.1. Product Description
  • 11.5.2. Regulatory Milestones
  • 11.5.3. Other Developmental Activities
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Product Profile
• 11.6. OPTUNE GIO: NOVOCURE
  • 11.6.1. Product Description
  • 11.6.2. Regulatory Milestones
  • 11.6.3. Other Developmental Activities
  • 11.6.4. Clinical Development
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Product Profile

12. EMERGING DRUGS

• 12.1. KEY COMPETITORS
• 12.2. ONC201: CHIMERIX
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
• 12.3. AV-GBM-1: AIVITA BIOMEDICAL
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
  • 12.3.4. Safety and Efficacy
• 12.4. ENZASTAURIN (DB-102): DENOVO BIOPHARMA
  • 12.4.1. Product Description
  • 12.4.2. Other Developmental Activities
  • 12.4.3. Clinical Development
  • 12.4.4. Safety and Efficacy
• 12.5. DCVAX-L: NORTHWEST THERAPEUTICS
  • 12.5.1. Product Description
  • 12.5.2. Other Developmental Activities
  • 12.5.3. Clinical Development
  • 12.5.4. Safety and Efficacy
• 12.6. EFLORNITHINE: ORBUS THERAPEUTICS
  • 12.6.1. Product Description
  • 12.6.2. Other Developmental Activities
  • 12.6.3. Clinical Development
• 12.7. TVI-BRAIN-1: TVAX BIOMEDICAL
  • 12.7.1. Product Description
  • 12.7.2. Other Developmental Activities
  • 12.7.3. Clinical Development
• 12.8. LAM561 (2-OHOA): LAMINAR PHARMACEUTICALS
  • 12.8.1. Product Description
  • 12.8.2. Other Developmental Activities
  • 12.8.3. Clinical Development
  • 12.8.4. Safety and Efficacy
• 12.9. REC-2282: RECURSION PHARMACEUTICALS
  • 12.9.1. Product Description
  • 12.9.2. Other Developmental Activities
  • 12.9.3. Clinical Development
• 12.1. VT1021: VIGEO THERAPEUTICS
  • 12.10.1. Product Description
  • 12.10.2. Other Developmental Activities
  • 12.10.3. Clinical Development
  • 12.10.4. Safety and Efficacy
• 12.11. VERZENIO (ABEMACICLIB): ELI LILLY
  • 12.11.1. Product Description
  • 12.11.2. Clinical Development
  • 12.11.3. Safety and Efficacy
• 12.12. PEMAZYRE (PEMIGATINIB): INCYTE CORPORATION
  • 12.12.1. Product Description
  • 12.12.2. Other Development Activities
  • 12.12.3. Clinical Development
• 12.13. PAXALISIB (GDC-0084): KAZIA THERAPEUTICS
  • 12.13.1. Product Description
  • 12.13.2. Other Developmental Activities
  • 12.13.3. Clinical Development
  • 12.13.4. Safety and Efficacy
• 12.14. BMX-001: BIOMIMETIX
  • 12.14.1. Product Description
  • 12.14.2. Other Developmental Activities
  • 12.14.3. Clinical Development
  • 12.14.4. Safety and Efficacy
• 12.15. BIZAXOFUSP (MDNA55): MEDICENNA THERAPEUTICS
  • 12.15.1. Product Description
  • 12.15.2. Other Developmental Activities
  • 12.15.3. Clinical Development
  • 12.15.4. Safety and Efficacy
• 12.16. ITI-1000 (PP65 DC VACCINE): IMMUNOMIC THERAPEUTICS
  • 12.16.1. Product Description
  • 12.16.2. Other Developmental Activities
  • 12.16.3. Clinical Development
  • 12.16.4. Safety and Efficacy
• 12.17. SURVAXM: MIMIVAX
  • 12.17.1. Product Description
  • 12.17.2. Other Developmental Activities
  • 12.17.3. Clinical Development
  • 12.17.4. Safety and Efficacy
• 12.18. OKN-007: OBLATO
  • 12.18.1. Product Description
  • 12.18.2. Other developmental Activities
  • 12.18.3. Clinical Development
  • 12.18.4. Safety and efficacy
• 12.19. BERUBICIN: CNS PHARMACEUTICALS
  • 12.19.1. Product Description
  • 12.19.2. Other Developmental Activities
  • 12.19.3. Clinical Development
  • 12.19.4. Safety and Efficacy
• 12.2. GLIOVAC/SITOIGANAP: EPITOPOIETIC RESEARCH CORPORATION (ERC)
  • 12.20.1. Product Description
  • 12.20.2. Other Developmental Activities
  • 12.20.3. Clinical Development
  • 12.20.4. Safety and efficacy
• 12.22. IGV-001: IMVAX
  • 12.22.1. Product Description
  • 12.22.2. Other Developmental Activities
  • 12.22.3. Clinical Development
  • 12.22.4. Safety and efficacy
• 12.23. BGB-290: BEIGENE
  • 12.23.1. Product Description
  • 12.23.2. Clinical Development
  • 12.23.3. Safety and Efficacy
• 12.24. EO2401: ENTEROME
  • 12.24.1. Product Description
  • 12.24.2. Other Developmental Activities
  • 12.24.3. Clinical Development
  • 12.24.4. Safety and Efficacy
• 12.25. VBI-1901: VBI VACCINES
  • 12.25.1. Product Description
  • 12.25.2. Other Developmental Activities
  • 12.25.3. Clinical Development
  • 12.25.4. Safety and Efficacy
• 12.26. TEMFERON: GENENTA SCIENCE
  • 12.26.1. Product Description
  • 12.26.2. Other Development Activities
  • 12.26.3. Clinical Development
  • 12.26.4. Safety and Efficacy
• 12.27. NOX-A12 (OLAPTESED PEGOL): TME PHARMA
  • 12.27.1. Product Description
  • 12.27.2. Other Developmental Activities
  • 12.27.3. Clinical Development
  • 12.27.4. Safety and Efficacy
• 12.28. INO-5401+ INO-9012+ LIBTAYO (CEMIPLIMAB): INOVIO PHARMACEUTICALS
  • 12.28.1. Product Description
  • 12.28.2. Other Developmental Activities
  • 12.28.3. Clinical Development
  • 12.28.4. Safety and Efficacy
• 12.29. LERAPOLTUREV: ISTARI ONCOLOGY
  • 12.29.1. Product Description
  • 12.29.2. Other Developmental Activities
  • 12.29.3. Clinical Development
  • 12.29.4. Safety and Efficacy
• 12.3. RHENIUM (186RE) OBISBEMEDA: PLUS THERAPEUTICS
  • 12.30.1. Product Description
  • 12.30.2. Other Developmental Activities
  • 12.30.3. Clinical Development
  • 12.30.4. Safety and Efficacy

13. GLIOMA: SEVEN MAJOR MARKET ANALYSIS

• 13.1. KEY FINDINGS
• 13.2. MARKET OUTLOOK
• 13.3. KEY MARKET FORECAST ASSUMPTIONS
  • 13.3.1. Cost Assumptions and Rebate
  • 13.3.2. Pricing Trends
  • 13.3.3. Analogue Assessment
  • 13.3.4. Launch Year and Therapy Uptake
• 13.4. CONJOINT ANALYSIS
• 13.5. TOTAL MARKET SIZE OF HGG IN THE 7MM
• 13.6. UNITED STATES MARKET SIZE
  • 13.6.1. Total Market Size of HGG in the United States
  • 13.6.2. Market Size of HGG by Therapies in the United States
• 13.7. EU4 AND THE UK MARKET SIZE
  • 13.7.1. Total Market Size of HGG in EU4 and the UK
  • 13.7.2. Market Size of HGG by Therapies in Germany
  • 13.7.3. Market Size of HGG by Therapies in France
  • 13.7.4. Market Size of HGG by Therapies in Italy
  • 13.7.5. Market Size of HGG by Therapies in Spain
  • 13.7.6. Market Size of HGG by Therapies in the UK
• 13.8. JAPAN MARKET SIZE
  • 13.8.1. Total Market Size of HGG in Japan
  • 13.8.2. Market Size of HGG by Therapies in Japan

14. UNMET NEEDS

15. SWOT

16. KOL VIEWS

17. MARKET ACCESS AND REIMBURSEMENT

• 17.1. UNITED STATES
• 17.2. EUROPE
• 17.3. JAPAN

18. APPENDIX

• 18.1. BIBLIOGRAPHY
• 18.2. REPORT METHODOLOGY

19. DELVEINSIGHT CAPABILITIES

20. DISCLAIMER

21. ABOUT DELVEINSIGHT